WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H558023
CAS#: 27959-26-8
Description: Nicomol is a niacin derivative with antilipidemic activity.
Hodoodo Cat#: H558023
Name: Nicomol
CAS#: 27959-26-8
Chemical Formula: C34H32N4O9
Exact Mass: 640.22
Molecular Weight: 640.649
Elemental Analysis: C, 63.74; H, 5.03; N, 8.75; O, 22.48
Synonym: Nicomol; Cholexamin; Cholexamine; K 31; K-31; K31;
IUPAC/Chemical Name: 2,2,6,6-Tetrakis(nicotinoyloxymethyl)cyclohexanol
InChi Key: VRAHPESAMYMDQI-UHFFFAOYSA-N
InChi Code: InChI=1S/C34H32N4O9/c39-28(24-6-1-12-35-16-24)44-20-33(21-45-29(40)25-7-2-13-36-17-25)10-5-11-34(32(33)43,22-46-30(41)26-8-3-14-37-18-26)23-47-31(42)27-9-4-15-38-19-27/h1-4,6-9,12-19,32,43H,5,10-11,20-23H2
SMILES Code: OC1C(COC(C2=CN=CC=C2)=O)(COC(C3=CN=CC=C3)=O)CCCC1(COC(C4=CN=CC=C4)=O)COC(C5=CN=CC=C5)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 640.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Shimoda K, Akiba T, Matsushima T, Rai T, Abe K, Hoshino M. [Niceritrol decreases serum phosphate levels in chronic hemodialysis patients]. Nihon Jinzo Gakkai Shi. 1998 Jan;40(1):1-7. Japanese. PMID: 9513376.
2: Shinozawa S, Gomita Y, Araki Y. Protective effects of various drugs on adriamycin (doxorubicin)-induced toxicity and microsomal lipid peroxidation in mice and rats. Biol Pharm Bull. 1993 Nov;16(11):1114-7. doi: 10.1248/bpb.16.1114. PMID: 8312867.
3: Yasui M, Ota K, Oshima A. Effects of ibudilast on calcium deposition in soft tissues of rabbits with atherosclerosis. J Int Med Res. 1990 Sep- Oct;18(5):415-24. doi: 10.1177/030006059001800510. PMID: 2257963.
4: Yoshikuni Y, Chokai S, Ozaki T, Yoshida H, Nakane M, Kuwabara K. Hypolipidemic effect of NS-1 and other related drugs in rhesus monkeys. Atherosclerosis. 1988 Nov;74(1-2):149-56. doi: 10.1016/0021-9150(88)90201-8. PMID: 3214474.
5: Shinozawa S, Gomita Y, Araki Y. Protection against adriamycin (doxorubicin)-induced toxicity in mice by several clinically used drugs. Acta Med Okayama. 1987 Feb;41(1):11-7. doi: 10.18926/AMO/31766. PMID: 2436440.
6: Watanabe T, Manna H, Suga T. Effects of some hypolipidemic drugs on biochemical values and on hepatic peroxisomal enzymes of normolipemic rat. J Pharmacobiodyn. 1981 Oct;4(10):743-50. doi: 10.1248/bpb1978.4.743. PMID: 6798192.
7: Ikeda S, Nagashima H, Taketa K, Watanabe M. Effect of nicomol on high density lipoprotein (HDL) subfractions, HDL2e and HDL3e, separated by electrophoresis. Acta Med Okayama. 1981 Apr;35(2):143-8. doi: 10.18926/AMO/31266. PMID: 6456646.
8: Watanabe M, Taketa K, Nagashima H, Yamamoto Y. Effect of nicomol on HDL cholesterol level. Acta Med Okayama. 1979 Aug;33(4):323-6. PMID: 227232.
9: Yamazaki N, Suzuki Y, Kamikawa T, Ogawa K, Mizutani K, Kakizawa N, Yamamoto M. Arrhythmogenic effects of acute free fatty acid mobilization on ischemic heart. Recent Adv Stud Cardiac Struct Metab. 1976 May 26-29;12:271-7. PMID: 201997.